Triple
T9812321
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | aflibercept |
E238303
|
entity |
| Predicate | usedWith |
P4791
|
FINISHED |
| Object |
FOLFIRI regimen
The FOLFIRI regimen is a combination chemotherapy protocol, typically including folinic acid, fluorouracil, and irinotecan, commonly used to treat advanced colorectal cancer.
|
E823219
|
NE FINISHED |
How this triple was built (4 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: FOLFIRI regimen | Statement: [aflibercept, usedWith, FOLFIRI regimen]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: FOLFIRI regimen Context triple: [aflibercept, usedWith, FOLFIRI regimen]
-
A.
BEACOPP regimen
The BEACOPP regimen is an intensive multi-drug chemotherapy protocol used primarily for advanced-stage Hodgkin lymphoma.
-
B.
R-CHOP
R-CHOP is a standard chemotherapy regimen combining rituximab with multiple cytotoxic drugs, commonly used to treat non-Hodgkin lymphoma.
-
C.
Xeloda
Xeloda is an oral chemotherapy drug (capecitabine) commonly used to treat various cancers, including colorectal and breast cancer.
-
D.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
-
E.
Avastin
Avastin is a widely used cancer drug (bevacizumab) that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF).
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg
Description generation
gpt-5.1
Instruction
Generate a one-sentence description of the target entity. You are given a context triple in the form (subject, predicate, object), where the object is the target entity. # Instructions Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. Avoid repeating the information from the triple, unless really essential. # Response Format Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: FOLFIRI regimen Triple: [aflibercept, usedWith, FOLFIRI regimen]
Generated description
The FOLFIRI regimen is a combination chemotherapy protocol, typically including folinic acid, fluorouracil, and irinotecan, commonly used to treat advanced colorectal cancer.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: FOLFIRI regimen Target entity description: The FOLFIRI regimen is a combination chemotherapy protocol, typically including folinic acid, fluorouracil, and irinotecan, commonly used to treat advanced colorectal cancer.
-
A.
BEACOPP regimen
The BEACOPP regimen is an intensive multi-drug chemotherapy protocol used primarily for advanced-stage Hodgkin lymphoma.
-
B.
R-CHOP
R-CHOP is a standard chemotherapy regimen combining rituximab with multiple cytotoxic drugs, commonly used to treat non-Hodgkin lymphoma.
-
C.
Xeloda
Xeloda is an oral chemotherapy drug (capecitabine) commonly used to treat various cancers, including colorectal and breast cancer.
-
D.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
-
E.
Avastin
Avastin is a widely used cancer drug (bevacizumab) that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF).
- F. None of above. chosen
Provenance (5 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69ca84defac48190abc1148804f184c1 |
completed | March 30, 2026, 2:12 p.m. |
| NER | Named-entity recognition | batch_69cdb222ba788190a9085272a3de7852 |
completed | April 2, 2026, 12:02 a.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69d1cc63c450819091e57030a48e7d88 |
completed | April 5, 2026, 2:43 a.m. |
| NEDg | Description generation | batch_69d1cce3d9d481909eaf7278dfe20955 |
completed | April 5, 2026, 2:45 a.m. |
| NED2 | Entity disambiguation (via description) | batch_69d1cd5d1670819085c58ff8889318af |
completed | April 5, 2026, 2:47 a.m. |
Created at: March 30, 2026, 8:30 p.m.